AB Science is stopping a late-stage clinical trial testing its oral drug masitinib as a treatment for progressive forms of multiple sclerosis (MS), saying this study and the therapy’s clinical development for MS are no longer a priority for the company. Instead, the developer will advance masitinib for…
Masitinib
Recommended Posts
- Probiotics linked to less fatigue and depression in relapsing-remitting MS
- US nonprofit launches $1B ‘Campaign to End MS,’ raises $12M on first day
- MRI marker cuts MS diagnosis time and avoids spinal taps, review finds
- Disrupted brain blood flow tied to poorer cognitive function in MS
- FDA grants priority review to ‘high-efficacy’ drug for 2 types of MS